Tuesday 3 September 2013

MarketResearchReports.com: Acute Coronary Syndrome - Pipeline Review, H2 2013, New Report Launched

Acute Coronary Syndrome - Pipeline Review, H2 2013
Acute Coronary Syndrome - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Acute Coronary Syndrome Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Acute Coronary Syndrome.
  • A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Spanning over 114 pages, 31 tables and 12 figures, “Acute Coronary Syndrome - Pipeline Review, H2 2013” report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Acute Coronary Syndrome Overview, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Acute Coronary Syndrome Therapeutics - Drug Profile Updates, Acute Coronary Syndrome Therapeutics - Discontinued Products, Acute Coronary Syndrome Therapeutics - Dormant Products, Acute Coronary Syndrome - Product Development Milestones. The report covers 17 companies F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Ligand Pharmaceuticals Incorporated, Medicure Inc., Arena Pharmaceuticals, Inc,. CSL Limited, LG Life Sciences, Ltd, Auspex Pharmaceuticals, Viron Therapeutics, Inc., Regado Biosciences, Cerenis Therapeutics SA Lacer, S.A., Lee's Pharmaceutical Holdings Limited and Ampio Pharmaceuticals, Inc.

Find all Diseases market research reports under a single page at: Diseases Market Research Reports

No comments:

Post a Comment

Note: only a member of this blog may post a comment.